

## Partnership in Korea for precision immuno-oncology therapeutics

29 August 2025 | News

### ACROBiosystems, DAAN Biotherapeutics to establish a multi-faceted collaboration framework



South Korea-based ACROBiosystems, a global biotechnology company dedicated to accelerating the drug development process through innovative tools and solutions, has entered into a strategic Memorandum of Understanding (MoU) with DAAN Biotherapeutics, a clinical-stage biotech focused on precision immuno-oncology therapeutics.

Through this agreement, the two companies will establish a multi-faceted collaboration framework including stable supply of high-performance bioreagents, technical cooperation for immuno-oncology drug development, and joint research and data sharing. This partnership aims to accelerate the research, development, and commercialisation of precision immunotherapies.

ACROBiosystems' main products and services include recombinant proteins, kits, antibodies, and scientific services. The company addresses critical challenges in cell and gene therapy (CGT) through its Resilient Supply™, which provides high-quality GMP-grade raw materials and quality control (QC) testing solutions with enhanced flexibility and regulatory compliance. Its GMP Manufacturing Base—featuring a smart modular design and dual ISO 9001/GMP certification—ensures agile production of cytokines, activation antibodies, nucleases, and matrix proteins for large-scale biopharmaceutical manufacturing. ACROBiosystems offers end-to-end support from development to commercialization, maintaining audit-ready compliance with global standards to mitigate supply chain risks and accelerate CGT innovation.

DAAN Biotherapeutics is gaining recognition as a clinical-stage biotech developing a proprietary precision immune-modulation platform that selectively activates T cells within the tumor microenvironment. By finely tuning the activation threshold of T cells, this next-generation immune-modulation technology is designed to overcome the toxicity and therapeutic resistance issues of conventional immunotherapies caused by non-specific stimulation, thereby enhancing efficacy while minimizing adverse effects.

The company is also expanding the applications of its platform to autoimmune and rare diseases. Its lead pipeline has completed preclinical development and is preparing for entry into global clinical trials.